HIV Drug "Lack Of Resistance" Claims Unlikely To Be Accepted By FDA
FDA is unlikely to include "statements describing lack of resistance" in labeling for new antiretroviral drugs, FDA Medical Officer Jeffrey Murray, MD, told a Nov. 3 meeting of the Antiviral Drugs Advisory Committee.
You may also be interested in...
Gilead has begun enrollment in two placebo-controlled trials of a 60 mg dose of adefovir dipivoxil that could provide sufficient evidence to prompt a reconsideration of the HIV therapy by FDA's Antiviral Drugs Advisory Committee.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials